ResMed's Stock Rises on Q1 Earnings and Revenue Beat, Margins Expand
RMD's stellar first-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.
| Ticker |
Sentiment |
Impact |
|
RMD
|
Bullish
|
42 %
|
|
DGX
|
Neutral
|
16 %
|
|
ISRG
|
Neutral
|
16 %
|
|
BSX
|
Neutral
|
16 %
|
